3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Conditions
Waldenstrom Macroglobulinemia
1
Thrombocythemia, Essential
1
TP53
1
Primary Myelofibrosis
1
Primary Malignant Neoplasm of Ovary
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Polycythemia Vera
1
Older Patients
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Monoclonal Gammopathy of Undetermined Significance
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Prolymphocytic
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Large Granular Lymphocytic
1
Interventions
Paclitaxel
1
Decitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Primary Malignant Neoplasm of Ovary
×
Decitabine
×
Other neoplasm
×
Clear all
NCT02159820
2014-06-10
DAC and CT
Chinese PLA General Hospital
Phase 2/3
Unknown
500 enrolled